Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Appoints New Director and Announces Resignation of Existing Director
Summary
On February 20, 2025, Terns Pharmaceuticals, Inc. announced the resignation of Dr. Carl Gordon from its Board of Directors, effective immediately. The Board appointed Robert Azelby as a new member, effective on the same date. Mr. Azelby, a seasoned biotechnology executive, was elected as a Class I director and will serve until the 2025 annual meeting of stockholders. He was also appointed to the Compensation Committee and will receive compensation and equity awards as per the Company's program for non-employee directors. A press release detailing these changes was issued on the same day.
Profitelligence Alerts
Get alerts for TERN
Be first to know when Terns Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic candidates targeting liver disease and oncology. Its primary function is to advance its pipeline of clinical and preclinical drug candidates that address significant unmet medical needs. One of the company's main focuses is on non-alcoholic steatohepatitis (NASH), a progressive liver disease. Through innovative approaches, Terns Pharmaceuticals explores various mechanisms to treat NASH, including small molecules designed to reduce liver inflammation and fibrosis. Beyond liver disease, the company is expanding its platform to include oncology, diversifying its impact in the healthcare industry. As a key player in the biopharmaceutical sector, Terns Pharmaceuticals Inc. contributes to the growing landscape of targeted therapies. With a dedicated emphasis on research and development, the company plays an essential role in pushing the boundaries of treatment options, potentially transforming the management of chronic liver diseases and cancer.
Official SEC Documents
Advertisement